^
    Back
    Association details:
    Biomarker:PTEN rs701848
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Breast Cancer
    Title:

    PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival

    Published date:
    12/20/2022
    Excerpt:
    PTEN rs701848 genotypes were analyzed in 160 HER2-positive metastatic breast cancer who received Trastuzumab therapy and clinically monitored for therapeutic response….PTEN rs701848 is deemed a significant predictor of Trastuzumab resistance and an independent prognostic factor of progression-free survival (PPFS)....PTEN rs701848 is significant predictor of trastuzumab resistance.
    DOI:
    10.1016/j.clbc.2022.12.010